08:13 AM EST, 01/10/2025 (MT Newswires) -- Vertex Pharmaceuticals ( VRTX ) and Zai Lab ( ZLAB ) said Friday they have signed a licensing deal to develop and commercialize povetacicept in mainland China, Hong Kong, Macau, Taiwan, and Singapore.

Zai Lab ( ZLAB ) will oversee clinical trials, regulatory submissions, and marketing in the licensed territory, the companies said.

Vertex will receive an upfront payment, regulatory milestone payments, and tiered royalties on net sales of the drug, they added.

Vertex's Povetacicept is being studied for the treatment of1 Immunoglobulin A nephropathy and other B cell-mediated diseases.